>

WEBINARS

RSS
>

MEETINGS / EVENTS

RSS
>

FDA MEDWATCH ALERTS

RSS

January 12, 2012

Respironics, Inc. Trilogy 100 Ventilators: Class I Recall - Device May Stop Delivering Therapy to Patient

Summary:

FDA notified health care professionals of the Class 1 recall of this product due to a manufacturing issue can stop delivering therapy to the patient. Part of the blower that circulates air and other gases through the ventilator may move out of position and cause the device to alarm.  Failure to respond could result in the potential for harm or death of a ventilator-dependent patient.

January 12, 2012

Bedford Laboratories Vecuronium Bromide And Polymyxin B For Injection USP For Injection: Recall - Glass Particles

Summary:

Bedford Laboratories issued guidance on the nationwide voluntary product recalls originally issued on August 2, 2011. The recalls were initiated after the discovery of a visible glass particle in a limited number of vials within the lots listed.

January 09, 2012

Endo Pharmaceuticals Opiate Products by Novartis Consumer Health: Public Health Advisory - Potential Safety Risk

Summary:

FDA is advising health care professionals and patients of a potential problem with opiate products manufactured and packaged for Endo Pharmaceuticals by Novartis Consumer Health at its Lincoln, Nebraska manufacturing site.

>

ASA FEATURED PRODUCT

Self-Education and Evaluation (SEE) Program

SKU: 30701-12CE

... Read more »

Single Copies, Member Price: $300

J&J Announces FDA Rejection of SEDASYS® Device

Chicago — (April 22, 2010) 

On Tuesday April 20, 2010 as reported by several media sources,1 2 Johnson & Johnson, parent company of Ethicon Endo Surgery, Inc., announced that the Food and Drug Administration (FDA) rejected its application for the SEDASYS® Computer-Assisted Personalized Sedation System. According to the reports, FDA sent the company a “not-approvable” letter after review of the application for, SEDASYS® which, through the use of a series of feedback and monitors, was designed to administer therapeutic levels of propofol to patients “undergoing colonoscopy and esophagoduodenoscopy procedures.”

The ASA had expressed concerns with the safety of the SEDASYS® system both in writing3 and during an FDA advisory panel hearing on the device back on May 28, 2009. However, following a presentation from the manufacturer and testimony from the public on the device, the advisory panel voted 8-2 that the device was “approvable with conditions.”4 Although reports indicate that the company will appeal the Agency’s decision, the final ruling contradicts the decision of the advisory panel and is a sound rejection of the application for the device.

In response to the news, ASA President, Dr. Alexander Hannenberg announced his strong support of the Agency’s decision and stated, “I am pleased that the FDA recognized the many unanswered questions and safety concerns about the device and the qualifications of those who sought to use it. ASA has a long history of advocating for patient safety and through its ruling on SEDASYS®, FDA has fulfilled its duty to protect patients; for that we are extremely grateful.”

  1. ASA comments to FDA
  2. FDA summary of the advisory committee meeting on May 28,2009

THE AMERICAN SOCIETY OF ANESTHESIOLOGISTS

Anesthesiologists: Physicians providing the lifeline of modern medicine. Founded in 1905, the American Society of Anesthesiologists is an educational, research and scientific association with 46,000 members organized to raise and maintain the standards of the medical practice of anesthesiology and improve the care of the patient.

For more information on the field of anesthesiology, visit the American Society of Anesthesiologists Web site at www.asahq.org. For patient information, visit LifeLineToModernMedicine.com

###

Contact:

Jennifer Gremmels
j.gremmels@asahq.org
847-268-9128